MedTrace Logo

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy

NCT02446717 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 141

Last updated 2017-09-15

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the efficacy and safety of ABT-493 and ABT-530 with or without ribavirin (RBV) in participants with chronic hepatitis C virus, (HCV)-infection who previously failed treatment with a direct acting antiviral (DAA)-containing regimen.

Conditions

  • Chronic Hepatitis C
  • Hepatitis C Virus
  • HCV
  • Direct-Acting Antiviral Agent (DAA)-Experienced

Interventions

DRUG

ABT-493, ABT-530

ABT-493 (tablet) dosed with ABT-530 (tablet)

DRUG

ribavirin (RBV)

Tablet

DRUG

ABT-493/ABT-530

Tablet; ABT-493 coformulated with ABT-530

Sponsors & Collaborators

Principal Investigators

  • AbbVie Inc · AbbVie

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2016-12-31
Completion
2017-01-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02446717 on ClinicalTrials.gov